Comparative Pharmacology
Head-to-head clinical analysis: CRESTOR versus EZETIMIBE AND SIMVASTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESTOR versus EZETIMIBE AND SIMVASTATIN.
CRESTOR vs EZETIMIBE AND SIMVASTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Ezetimibe inhibits intestinal cholesterol absorption by binding to the Niemann-Pick C1-Like 1 (NPC1L1) transporter at the brush border of enterocytes, reducing delivery of cholesterol to the liver. Simvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.
Oral, 5-40 mg once daily. Initial dose typically 10-20 mg; max 40 mg.
10 mg ezetimibe / 20 mg simvastatin orally once daily in the evening, with or without food; may titrate up to maximum of 10 mg ezetimibe / 40 mg simvastatin once daily; avoid doses >40 mg simvastatin unless already tolerated for ≥12 months.
None Documented
None Documented
The terminal elimination half-life is approximately 19 hours (range 13–20 hours). This long half-life allows once-daily dosing and provides sustained HMG-CoA reductase inhibition.
Ezetimibe: terminal half-life is approximately 22 hours for ezetimibe and its glucuronide conjugate, allowing once-daily dosing. Simvastatin: terminal half-life is about 2-3 hours for the active metabolite, but the prodrug simvastatin has a shorter half-life (~2 hours); clinical effect persists due to inhibition of HMG-CoA reductase.
Approximately 90% of rosuvastatin is eliminated in feces (as unchanged drug and metabolites), and about 10% is excreted in urine (mainly as unchanged drug). Biliary excretion is the primary route for elimination of metabolites.
Ezetimibe is primarily excreted in feces (78%) as unchanged drug and glucuronide conjugate, with minimal renal excretion (11%). Simvastatin is excreted via biliary/fecal route (60%) as active metabolites and unchanged drug; renal excretion accounts for approximately 13% of the dose.
Category C
Category D/X
Statin
Statin